Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Naremaddepalli S. Sudarshan"'
Autor:
Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi, Raghuveer K. Ramachandra, Dodderi S. Samiulla, Anirudha Lakshminarasimhan, Anuradha Ramanathan, Talapaneni Chandrasekhar, Amit A. Dhudashiya, Sumalatha R. Talapati, Nagesh Gowda, Sreenivasulareddy Palakolanu, Jiju Mani, Bandi Srinivasrao, David Joseph, Nigam Kumar, Rashmi Nair, Hanudatta S. Atreya, Nagaraj Gowda, Murali Ramachandra
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-12 (2021)
Sasikumar et al. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. They find that CA-170 activates T cells and exhibits anti-tumor efficacy in mouse models. This study highlights the potential
Externí odkaz:
https://doaj.org/article/0dc6fdd12b8e4be4a3c38267bc1cd96a
Publikováno v:
Protein & Peptide Letters. 16:1029-1035
We report a one pot synthesis of Fmoc amino acid derived 4-amino-thiazole derivatives and thiazole linked N-orthogonally protected dipeptidomimetics by the condensation of N(alpha)-Fmoc alpha-halomethylketones with thiourea and Boc/Z-alpha-amino acid
Publikováno v:
Synthetic Communications. 38:2625-2637
The synthesis of peptides employing Fmoc-amino acid chlorides in presence of HOBt·DCHA salt in solution as well as by the solid-phase methods is described. The coupling was found to be complete in 30 min and free from racemization. The synthesis of
Publikováno v:
Synthetic Communications. 38:2168-2184
The synthesis of O-succinimidyl-(tert-butoxycarbonylamino)methyl carbamates employing isocyanates made through the Curtius rearrangement of Boc-amino acid azides in the presence of N-hydroxysuccinimide under the influence of ultrasound is described.
Publikováno v:
International Journal of Peptide Research and Therapeutics. 14:149-156
A simple protocol for the synthesis of linear peptidylcarbamates employing Fmoc-β-aminoalkoxy carbonyl chlorides is described. The N-Fmoc-β-aminoalkoxy carbonyl chlorides were prepared by the reaction of phosgene or triphosgene with Fmoc-protected
Publikováno v:
International Journal of Peptide Research and Therapeutics. 14:105-112
This work describes the utility of Bsmoc group in the synthesis of ureidopeptides and peptidyl ureas. The reaction of isocyanates derived from Bsmoc-α-amino acids with amino acid ester has yielded the ureidopeptides in good yields. The isocyanates w
Publikováno v:
International Journal of Peptide Research and Therapeutics. 13:393-397
A general and efficient method has been developed for the alcoholysis of isocyanates derived from the Nα-[(9-fluorenylmethyl)oxy]carbonyl amino acids with various alcohols including hindered ones assisted by MW irradiation. Thus, the synthesis of N,
Autor:
Sanjeev Giri, Naremaddepalli S. Sudarshan, Adam S. Lazorchak, DS Samiulla, Murali Ramachandra, Tim Wyant, Rajesh Eswarappa, Nagaraj Gowda, Yueyun Ding, Pottayil G. Sasikumar, David Tuck, Raghuveer Ramachandra, Troy Patterson
Publikováno v:
Cancer Immunology Research. 5:A36-A36
The clinical success of antibody-mediated immune checkpoint blockade therapies has transformed the cancer therapy paradigm by demonstrating that durable antitumor immune responses and long-term remissions may be achieved in a subset of patients acros
Synthesis of N-urethane Protected β-Amino Alcohols Employing N-(protected-α-aminoacyl)benzotriazoles
Publikováno v:
Journal of Chemical Research. 2007:683-685
A simple and racemisation-free synthesis of N-urethane protected α-amino/peptidyl alcohols by the reduction of the corresponding easily accessible N-acylbenzotriazoles is described. The method is practical, straightforward, fast and efficient for th
Autor:
Sharad Singh, Naremaddepalli S. Sudarshan, Pottayil G. Sasikumar, Sreenivas Adurthi, T Chandrasekhar, Nagaraj Gowda, Rashmi Nair, Jiju Mani, Nagesh Gowda, DS Samiulla, Raghuveer Ramachandra, Amit Dhudashia, Murali Ramachandra
Publikováno v:
Cancer Research. 76:4861-4861
Recent successes in achieving highly durable clinical responses with antibodies to immune checkpoint receptors such as CTLA4 and PD1 have transformed the outlook for cancer therapy. While these antibody-based therapies show impressive clinical activi